Downregulating inos to increase car-t killing
AssigneeH. Lee Moffitt Cancer Center and Research Institute, Inc.
InventorsMarco DAVILA, Sae Bom LEE
Life of this patent
Estimating the term…
Abstract
Chimeric antigen receptor (CAR) T cell therapies have revolutionized the treatment of B cell malignancies, but a significant proportion of patients with large B cell lymphoma (LBCL) experience primary resistance or relapse after CAR T cell treatment. As disclosed herein, anti-inflammatory macrophages suppress CAR-T cell expansion, induce death, and reduce CAR expression. Disclosed is a method for enhancing anti-tumor efficacy of immune effector cells, such as CAR-T cells, in a subject that involves administering to the subject a nitric oxide synthase (NOS) inhibitor.
Claims10
A method for enhancing anti-tumor efficacy of immune effector cells in a subject, comprising administering to the subject an effective amount of a composition comprising a nitric oxide synthase (NOS) inhibitor, interferon gamma (IFN-γ) inhibitor, or combination thereof.
Dependencies are inferred from the claim text.